Raynauds fenomen (Norwegian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Raynauds fenomen" in Norwegian language version.

refsWebsite

Global rank Norwegian rank

21nih.gov

4^th place

23^rd place

17doi.org

2^nd place

9^th place

4archive.org

6^th place

42^nd place

1mercksource.com

8,363^rd place

9,790^th place

1web.archive.org

1^st place

1masson.fr

low place

1ahajournals.org

3,608^th place

6,245^th place

ahajournals.org

circ.ahajournals.org

Fries R, Shariat K, von Wilmowsky H, Böhm M (2005). «Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy». Circulation. 112 (19): 2980–5. PMID 16275885. doi:10.1161/CIRCULATIONAHA.104.523324 (inaktiv 2010-02-15).

archive.org

Anderson ME, Moore TL, Lunt M, Herrick AL (2007). «The 'distal-dorsal difference': a thermographic parameter by which to differentiate between primary and secondary Raynaud's phenomenon». Rheumatology. 46 (3): 533–8. PMID 17018538. doi:10.1093/rheumatology/kel330.
Pancera P, Sansone S, Secchi S, Covi G, Lechi A (1997). «The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud's phenomenon». Journal of Internal Medicine. 242 (5): 373–6. PMID 9408065. doi:10.1046/j.1365-2796.1997.00219.x.
Karavidas MK, Tsai PS, Yucha C, McGrady A, Lehrer PM (2006). «Thermal biofeedback for primary Raynaud's phenomenon: a review of the literature». Applied Psychophysiology and Biofeedback. 31 (3): 203–16. PMID 17016765. doi:10.1007/s10484-006-9018-2.
DiGiacomo RA, Kremer JM, Shah DM (1989). «Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study». The American Journal of Medicine. 86 (2): 158–64. PMID 2536517. doi:10.1016/0002-9343(89)90261-1.

doi.org

Anderson ME, Moore TL, Lunt M, Herrick AL (2007). «The 'distal-dorsal difference': a thermographic parameter by which to differentiate between primary and secondary Raynaud's phenomenon». Rheumatology. 46 (3): 533–8. PMID 17018538. doi:10.1093/rheumatology/kel330.
Hirschl M, Hirschl K, Lenz M, Katzenschlager R, Hutter HP, Kundi M (2006). «Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance». Arthritis and Rheumatism. 54 (6): 1974–81. PMID 16732585. doi:10.1002/art.21912.
Holmen OL, Backe B (2009). «An underdiagnosed cause of nipple pain presented on a camera phone». BMJ. 339: b2553. doi:10.1136/bmj.b2553.
Anderson JE, Held N, Wright K (2004). «Raynaud's phenomenon of the nipple: a treatable cause of painful breastfeeding». Pediatrics. 113 (4): e360–4. PMID 15060268. doi:10.1542/peds.113.4.e360.
Gayraud M (2007). «Raynaud's phenomenon». Joint, Bone, Spine. 74 (1): e1–8. PMID 17218139. doi:10.1016/j.jbspin.2006.07.002.
Berlin AL, Pehr K (2004). «Coexistence of erythromelalgia and Raynaud's phenomenon». Journal of the American Academy of Dermatology. 50 (3): 456–60. PMID 14988692. doi:10.1016/S0190-9622(03)02121-2.
Smith CR, Rodeheffer RJ (1985). «Raynaud's phenomenon: pathophysiologic features and treatment with calcium-channel blockers». The American Journal of Cardiology. 55 (3): 154B–157B. PMID 3881908. doi:10.1016/0002-9149(85)90625-3.
Pancera P, Sansone S, Secchi S, Covi G, Lechi A (1997). «The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud's phenomenon». Journal of Internal Medicine. 242 (5): 373–6. PMID 9408065. doi:10.1046/j.1365-2796.1997.00219.x.
Dziadzio M, Denton CP, Smith R; m.fl. (1999). «Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial». Arthritis and Rheumatism. 42 (12): 2646–55. PMID 10616013. doi:10.1002/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T.
Waldo R (1979). «Prazosin relieves Raynaud's vasospasm». JAMA. 241 (10): 1037. PMID 762741. doi:10.1001/jama.241.10.1037.
Wang WH, Lai CS, Chang KP; m.fl. (2006). «Peripheral sympathectomy for Raynaud's phenomenon: a salvage procedure». The Kaohsiung Journal of Medical Sciences. 22 (10): 491–9. PMID 17098681. doi:10.1016/S1607-551X(09)70343-2.
Neumeister MW, Chambers CB, Herron MS; m.fl. (2009). «Botox therapy for ischemic digits». Plastic and Reconstructive Surgery. 124 (1): 191–201. PMID 19568080. doi:10.1097/PRS.0b013e3181a80576.
Van Beek AL, Lim PK, Gear AJ, Pritzker MR (2007). «Management of vasospastic disorders with botulinum toxin A». Plastic and Reconstructive Surgery. 119 (1): 217–26. PMID 17255677. doi:10.1097/01.prs.0000244860.00674.57.
Muir AH, Robb R, McLaren M, Daly F, Belch JJ (2002). «The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trial». Vascular Medicine. 7 (4): 265–7. PMID 12710841. doi:10.1191/1358863x02vm455oa.
Tucker AT, Pearson RM, Cooke ED, Benjamin N (1999). «Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud's syndrome: a randomised trial». Lancet. 354 (9191): 1670–5. PMID 10568568. doi:10.1016/S0140-6736(99)04095-7.
Karavidas MK, Tsai PS, Yucha C, McGrady A, Lehrer PM (2006). «Thermal biofeedback for primary Raynaud's phenomenon: a review of the literature». Applied Psychophysiology and Biofeedback. 31 (3): 203–16. PMID 17016765. doi:10.1007/s10484-006-9018-2.
DiGiacomo RA, Kremer JM, Shah DM (1989). «Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study». The American Journal of Medicine. 86 (2): 158–64. PMID 2536517. doi:10.1016/0002-9343(89)90261-1.

masson.fr

Pistorius MA, Planchon B, Schott JJ, Lemarec H (2006). «[Heredity and genetic aspects of Raynaud's disease]». Journal Des Maladies Vasculaires. 31 (1): 10–5. PMID 16609626. Arkivert fra originalen 28. mars 2020. Besøkt 16. mai 2010.

mercksource.com

Raynaud disease at Dorland's Medical Dictionary

nih.gov

ncbi.nlm.nih.gov

Anderson ME, Moore TL, Lunt M, Herrick AL (2007). «The 'distal-dorsal difference': a thermographic parameter by which to differentiate between primary and secondary Raynaud's phenomenon». Rheumatology. 46 (3): 533–8. PMID 17018538. doi:10.1093/rheumatology/kel330.
Hirschl M, Hirschl K, Lenz M, Katzenschlager R, Hutter HP, Kundi M (2006). «Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance». Arthritis and Rheumatism. 54 (6): 1974–81. PMID 16732585. doi:10.1002/art.21912.
Anderson JE, Held N, Wright K (2004). «Raynaud's phenomenon of the nipple: a treatable cause of painful breastfeeding». Pediatrics. 113 (4): e360–4. PMID 15060268. doi:10.1542/peds.113.4.e360.
Pistorius MA, Planchon B, Schott JJ, Lemarec H (2006). «[Heredity and genetic aspects of Raynaud's disease]». Journal Des Maladies Vasculaires. 31 (1): 10–5. PMID 16609626. Arkivert fra originalen 28. mars 2020. Besøkt 16. mai 2010.
Gayraud M (2007). «Raynaud's phenomenon». Joint, Bone, Spine. 74 (1): e1–8. PMID 17218139. doi:10.1016/j.jbspin.2006.07.002.
Berlin AL, Pehr K (2004). «Coexistence of erythromelalgia and Raynaud's phenomenon». Journal of the American Academy of Dermatology. 50 (3): 456–60. PMID 14988692. doi:10.1016/S0190-9622(03)02121-2.
Priollet P (1998). «[Raynaud's phenomena: diagnostic and treatment study]». La Revue Du Praticien. 48 (15): 1659–64. PMID 9814067.
Kahan A, Weber S, Amor B, Saporta L, Hodara M, Degeorges M (1981). «Nifedipine and Raynaud's phenomenon». Annals of Internal Medicine. 94 (4 pt 1): 546. PMID 7212523.
Kahan A, Weber S, Amor B, Saporta L, Hodara M, Degeorges M (1982). «[Controlled study of nifedipine in the treatment of Raynaud's phenomenon]». Revue Du Rhumatisme et Des Maladies Ostéo-articulaires. 49 (5): 337–43. PMID 6285445.
Smith CR, Rodeheffer RJ (1985). «Raynaud's phenomenon: pathophysiologic features and treatment with calcium-channel blockers». The American Journal of Cardiology. 55 (3): 154B–157B. PMID 3881908. doi:10.1016/0002-9149(85)90625-3.
Pancera P, Sansone S, Secchi S, Covi G, Lechi A (1997). «The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud's phenomenon». Journal of Internal Medicine. 242 (5): 373–6. PMID 9408065. doi:10.1046/j.1365-2796.1997.00219.x.
Dziadzio M, Denton CP, Smith R; m.fl. (1999). «Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial». Arthritis and Rheumatism. 42 (12): 2646–55. PMID 10616013. doi:10.1002/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T.
Waldo R (1979). «Prazosin relieves Raynaud's vasospasm». JAMA. 241 (10): 1037. PMID 762741. doi:10.1001/jama.241.10.1037.
Fries R, Shariat K, von Wilmowsky H, Böhm M (2005). «Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy». Circulation. 112 (19): 2980–5. PMID 16275885. doi:10.1161/CIRCULATIONAHA.104.523324 (inaktiv 2010-02-15).
Wang WH, Lai CS, Chang KP; m.fl. (2006). «Peripheral sympathectomy for Raynaud's phenomenon: a salvage procedure». The Kaohsiung Journal of Medical Sciences. 22 (10): 491–9. PMID 17098681. doi:10.1016/S1607-551X(09)70343-2.
Neumeister MW, Chambers CB, Herron MS; m.fl. (2009). «Botox therapy for ischemic digits». Plastic and Reconstructive Surgery. 124 (1): 191–201. PMID 19568080. doi:10.1097/PRS.0b013e3181a80576.
Van Beek AL, Lim PK, Gear AJ, Pritzker MR (2007). «Management of vasospastic disorders with botulinum toxin A». Plastic and Reconstructive Surgery. 119 (1): 217–26. PMID 17255677. doi:10.1097/01.prs.0000244860.00674.57.
Muir AH, Robb R, McLaren M, Daly F, Belch JJ (2002). «The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trial». Vascular Medicine. 7 (4): 265–7. PMID 12710841. doi:10.1191/1358863x02vm455oa.
Tucker AT, Pearson RM, Cooke ED, Benjamin N (1999). «Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud's syndrome: a randomised trial». Lancet. 354 (9191): 1670–5. PMID 10568568. doi:10.1016/S0140-6736(99)04095-7.
Karavidas MK, Tsai PS, Yucha C, McGrady A, Lehrer PM (2006). «Thermal biofeedback for primary Raynaud's phenomenon: a review of the literature». Applied Psychophysiology and Biofeedback. 31 (3): 203–16. PMID 17016765. doi:10.1007/s10484-006-9018-2.
DiGiacomo RA, Kremer JM, Shah DM (1989). «Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study». The American Journal of Medicine. 86 (2): 158–64. PMID 2536517. doi:10.1016/0002-9343(89)90261-1.

web.archive.org

Pistorius MA, Planchon B, Schott JJ, Lemarec H (2006). «[Heredity and genetic aspects of Raynaud's disease]». Journal Des Maladies Vasculaires. 31 (1): 10–5. PMID 16609626. Arkivert fra originalen 28. mars 2020. Besøkt 16. mai 2010.